(2R,3R,4R,5R)-5-(6-amino-9H-purin-9-yl)-2-(hydroxymethyl)-4-((4-methoxybenzyl)oxy)tetrahydrofuran-3-ol | 80015-54-9

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘌呤核苷
• 英文名称: (2R,3R,4R,5R)-5-(6-amino-9H-purin-9-yl)-2-(hydroxymethyl)-4-((4-methoxybenzyl)oxy)tetrahydrofuran-3-ol
• 英文别名: 2'-O-(4-methoxybenzyl)adenosine；2'-O-(p-methoxybenzyl)adenosine；(2R,3R,4R,5R)-5-(6-aminopurin-9-yl)-2-(hydroxymethyl)-4-[(4-methoxyphenyl)methoxy]oxolan-3-ol
• CAS: 80015-54-9
• 化学式: C₁₈H₂₁N₅O₅
• 分子量: 387.395
• InChiKey: BXCZKVWMLNIKCC-SCFUHWHPSA-N

物化性质

• 熔点：
  156 °C
• 沸点：
  702.1±70.0 °C(Predicted)
• 密度：
  1.59±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  28
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.39
• 拓扑面积：
  138
• 氢给体数：
  3
• 氢受体数：
  9

反应信息

• 作为反应物：
  描述：

  (2R,3R,4R,5R)-5-(6-amino-9H-purin-9-yl)-2-(hydroxymethyl)-4-((4-methoxybenzyl)oxy)tetrahydrofuran-3-ol 在 吡啶 、 氯化亚砜 、 potassium tert-butylate 、 lithium hydroxide 作用下， 以 1,4-二氧六环 、 乙腈 为溶剂， 生成
  参考文献：
  名称：

  Structure-Guided Design of Fluorescent S-Adenosylmethionine Analogs for a High-Throughput Screen to Target SAM-I Riboswitch RNAs

  摘要：

  Many classes of S-adenosylmethionine (SAM)-binding RNAs and proteins are of interest as potential drug targets in diverse therapeutic areas, from infectious diseases to cancer. In the former case, the SAM-I riboswitch is an attractive target because this structured RNA element is found only in bacterial mRNAs and regulates multiple genes in several human pathogens. Here, we describe the synthesis of stable and fluorescent analogs of SAM in which the fluorophore is introduced through a functionalizable linker to the ribose. A Cy5-labeled SAM analog was shown to bind several SAM-I riboswitches via in-line probing and fluorescence polarization assays, including one from Staphylococcus aureus that controls the expression of SAM synthetase in this organism. A fluorescent ligand displacement assay was developed and validated for high-throughput screening of compounds to target the SAM-I riboswitch class.

  DOI：

  10.1016/j.chembiol.2014.01.004
• 作为产物：
  描述：

  4-甲氧基溴苄 、 腺苷 在 sodium hydride 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 2.83h， 以65%的产率得到(2R,3R,4R,5R)-5-(6-amino-9H-purin-9-yl)-2-(hydroxymethyl)-4-((4-methoxybenzyl)oxy)tetrahydrofuran-3-ol
  参考文献：
  名称：

  4-甲氧基苄基作为腺苷2'-羟基新保护基团合成寡核苷酸

  摘要：

  4-甲氧基苄基在氢化钠存在下直接引入腺苷与4-甲氧基苄基溴反应的2'-羟基中。2'-O-(4-甲氧基苄基)腺苷可成功用于通过磷酸三酯法合成寡核糖核苷酸。4-甲氧基苄基通过氟硼酸三苯甲酯从寡核糖核苷酸中快速去除，并且完全解封闭的寡核糖核苷酸通过酶水解表征。

  DOI：

  10.1246/cl.1982.189

文献信息

• [EN] DC-SIGN ANTIBODY CONJUGATES COMPRISING STING AGONISTS<br/>[FR] CONJUGUÉS D'ANTICORPS DC-SIGN COMPRENANT DES AGONISTES DE STING
  申请人：NOVARTIS AG

  公开号：WO2020092617A1

  公开（公告）日：2020-05-07

  Provided herein are immunoconjugates comprising an anti-DC-SiGN antibody conjugated to a STING agonist. Also disclosed are methods of making the immunoconjugates and methods of treating cancer using the immunoconjugates.

  本文件提供了包含抗-DC-SiGN抗体与STING激动剂偶联的免疫偶联物。还公开了制造免疫偶联物的方法以及使用免疫偶联物治疗癌症的方法。
• [EN] CYCLIC DINUCLEOTIDES AS STING AGONISTS<br/>[FR] DINUCLÉOTIDES CYCLIQUES UTILISÉS EN TANT QU'AGONISTES DE STING
  申请人：JANSSEN BIOTECH INC

  公开号：WO2019118839A1

  公开（公告）日：2019-06-20

  Disclosed are compounds, compositions and methods for treating of diseases, syndromes, or disorders that are affected by the modulation of STING. Such compounds are represented by Formula (I) as follows: wherein B2,X2, R2a, R2b, R2c, Z-M-Y, Y1-M1Z1, B1, X1, R1a, R1b, R1c are as defined herein.

  揭示了一种通过调节STING来治疗受影响的疾病、综合征或紊乱的化合物、组合物和方法。这些化合物由以下式（I）表示：其中B2、X2、R2a、R2b、R2c、Z-M-Y、Y1-M1Z1、B1、X1、R1a、R1b、R1c如本文所定义。
• LOCKED NUCLEIC ACID CYCLIC DINUCLEOTIDE COMPOUNDS AND USES THEREOF
  申请人：ADURO BIOTECH, INC.

  公开号：US20190185511A1

  公开（公告）日：2019-06-20

  The present invention provides highly active locked nucleic acid cyclic-dinucleotide (LNA-CDN) immune stimulators that activate DCs via the cytoplasmic receptor known as STING (Stimulator of Interferon Genes). In particular, the LNA-CDNs of the present invention are provided in the form of a composition comprising one or more cyclic dinucleotides that induce human STING-dependent type I interferon production, wherein the cyclic dinucleotides present in the composition have at least one 2′, 4′ locked nucleic acids within the cyclic dinucleotide.

  本发明提供了高活性的锁定核酸环二核苷酸（LNA-CDN）免疫刺激剂，通过细胞质受体STING（干扰素基因刺激剂）激活DCs。具体而言，本发明的LNA-CDNs以一种组合物的形式提供，该组合物包括一种或多种诱导人类STING依赖型I型干扰素产生的环二核苷酸，其中组合物中的环二核苷酸至少有一个2′, 4′锁定核酸。
• Bis 2′-5′-RR-(3′F-A)(3′F-A) cyclic dinucleotide compound and uses thereof
  申请人：ADURO BIOTECH, INC.

  公开号：US10975114B2

  公开（公告）日：2021-04-13

  The present invention provides the cyclic dinucleotide compound 2′2′-RR-(3′F-A)(3′F-A) as a highly active immune stimulator that activates DCs via the cytoplasmic receptor known as STING (Stimulator of Interferon Genes), and compositions and uses thereof.

  本发明提供了环二核苷酸化合物2′2′-RR-(3′F-A)(3′F-A)，作为一种高活性的免疫刺激剂，通过细胞质受体STING（干扰素基因刺激剂）激活DCs，以及其组合物和用途。
• [EN] COMPOSITIONS AND METHODS OF MODULATING THE IMMUNE RESPONSE BY ACTIVATING ALPHA PROTEIN KINASE 1<br/>[FR] COMPOSITIONS ET PROCÉDÉS DE MODULATION DE LA RÉPONSE IMMUNITAIRE PAR ACTIVATION DE LA PROTÉINE KINASE ALPHA 1
  申请人：SHANGHAI YAO YUAN BIOTECHNOLOGY CO LTD

  公开号：WO2019080898A1

  公开（公告）日：2019-05-02

  The disclosure provides compositions and methods related to activating alpha-kinase 1 (ALPK1) for modulating an immune response and treating or preventing cancer, infection, inflammation and related diseases and disorders as well as potentiating an immune response to a target antigen. The disclosure also provides heterocyclic compounds of formula (I) as agonists of alpha protein kinase 1 (ALPK1) and their use in activating ALPK1, modulating an immune response and treating diseases such as cancer, wherein A1, A2, L1, L2, L3, Z1, Z2, W1, W2, R1, R2, R3, R4, R5, R6 and R7 are defined herein.

  该披露提供了与激活α-激酶1（ALPK1）相关的组合物和方法，用于调节免疫应答，治疗或预防癌症、感染、炎症和相关疾病和疾病，以及增强对靶抗原的免疫应答。该披露还提供了式（I）的杂环化合物作为α蛋白激酶1（ALPK1）的激动剂，并其在激活ALPK1、调节免疫应答和治疗癌症等疾病中的应用，其中A1、A2、L1、L2、L3、Z1、Z2、W1、W2、R1、R2、R3、R4、R5、R6和R7在此定义。